[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-433737-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-433737-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","winners-of-the-2022-honor-awards-for-excellence-at-the-annual-meeting-of-the-chinese-medical-association-taipei-part-iv","Winners of the 2022 honor awards for excellence at the annual meeting of the Chinese Medical Association-Taipei - Part IV","","Editorial overview of Part IV in a 2023 special issue recognizing the 2022 Excellent Research Paper Awards at the Chinese Medical Association–Taipei Annual Meeting. Highlights focus on cancer immuno-oncology and the challenge of recurrent or loco-regional and metastatic head and neck squamous cell carcinoma progressed after immune checkpoint inhibitors. Summarizes a cetuximab post-ICI evaluation in 28 patients with reported response and disease control rates, but limited survival outcomes, emphasizing poor prognosis and the need for precision oncology candidate selection and improved radiosensitizing strategies.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/winners-of-the-2022-honor-awards-for-excellence-at-the-annual-meeting-of-the-chinese-medical-association-taipei-part-iv/433737/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/winners-of-the-2022-honor-awards-for-excellence-at-the-annual-meeting-of-the-chinese-medical-association-taipei-part-iv/433737.png","ImageObject",300,407,{"name":42,"@type":43},"Ivy","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-29",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What treatment challenge does the editorial address in recurrent or metastatic HNSCC?","Question",{"text":63,"@type":64},"It addresses patients with recurrent (or loco-regional) and metastatic head and neck squamous cell carcinoma who progressed after immune checkpoint inhibitors, highlighting the difficulty of improving outcomes.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was cetuximab evaluated after progression on ICIs, and what were the key results?",{"text":68,"@type":64},"The study enrolled 28 patients and reported objective response rate and disease control rate, with median progression-free survival of 2.9 months and median overall survival of 8.4 months.",{"name":70,"@type":61,"acceptedAnswer":71},"Why does the editorial argue that neither cetuximab nor ICIs work effectively as front-line radiosensitizers?",{"text":72,"@type":64},"It notes lack of significant survival improvement when cetuximab is added to CRT and when ICIs are combined with CRT, and therefore positions radiosensitizing systemic therapy as an unmet need requiring new agents and strategy design.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},433737,1790929894,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":26,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":97,"preview_page_count":4},549758252649,"https://ap-avatar.wpscdn.com/avatar/8000253669c5317157?_k=1778319167496531819","J Chin MedAssoc  \nEditorial  \nWinners of the 2022 honor awards for excellence at the annual meeting of the Chinese Medical Association-Taipei: Part IV  \nPeng-Hui Wanga,b,c,* , Teh-Ia Huod,e  \naDepartment of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC; bInstitute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC; cFemale Cancer Foundation, Taipei, Taiwan, ROC; dDepartment of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, ROC; eInstitute of Pharmacology, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC  \nIn the series of special issue to address the 2022 Excellent Research Paper Awards of the Journal of the Chinese Medical Association (JCMA) at the Chinese Medical Association-Taipei Annual Meeting (CMA-Taipei) on July 8 and July 9, 2023, held at Taipei, Taiwan, this part IV is an end point. The outstanding cancer research honor is given to Dr. Lai, who is involved in the very hot topic addressing a biggest challenge of patients with recurrent (or loco-regional) and metastatic head and necksquamous cell carcinoma (R/M HNSCC) who have been treated with the immune checkpoint inhibitors (ICIs) but diseases progressed.1 Immuno-oncology is one of the leading therapeutic advanced therapies for cancer patients, not only due to successful transformation of the treatment landscape but also clear prediction of outcomes with assistance of molecular-pathological findings.2–6  \nDr. Lai and colleagues attempted to evaluate the effectiveness of the anti-epidermal growth factor receptor (EGFR) monoclonal antibody cetuximab for the treatment of HNSCC patients after progression on ICIs.1 The 28 patients were enrolled with objective response rate (ORR) of 32.1% (95% CI, 17.9% - 50.6%) and disease control rate (DCR) of 53.6%(95% CI, 42.4%-6.4%), respectively.1 Additionally, the ORR and DCR were similar in patients either with loco-regional or metastatic HNSCC (30.7% vs 33.3%; 53.8% vs 53.3%, respectively) .1 However, median progression-free survival (mPFS) and median overall survival (mOS) were only 2.9 and 8.4 months, respectively.1 Although mPFS was similar between patients with locoregional or metastatic HNSCC (3.2 vs 2.9 months), the mOS was dramatically different between both groups. Patients with loco-regional HNSCC had a significantly prolonged mOS (13.6 months) than those with metastatic HNSCC (5 .7 months) did.1 Although the authors concluded that a cetuximab-based regimen is an effective and tolerable treatment for loco-regional or  \n* Address correspondence. Dr. Peng-Hui Wang, Department of Obstetricsand Gynecology, Taipei Veterans General Hospital, 201, Section 2, Shi-Pai Road, Taipei 112, Taiwan, [ROC. E-mail address: phwang@vghtpe.gov.tw](ROC. E-mail address: phwang@vghtpe.gov.tw);  \n[pongpongwang@gmail.com](pongpongwang@gmail.com) (P.-H. Wang).  \nConflicts of interest: Dr Peng-Hui Wang and Dr Teh-Ia Huo, editorial board members at the Journal of the Chinese Medical Association, have no roles in the peer review process of or decision to publish this article. Both authors declare that they have no conflicts of interest related to the subject matter or materials discussed in this article.  \nJournal of Chinese Medical Association. (2024) 87: 1-2.  \nReceived date: July 27, 2023 Accepted date: November 16, 2023.  \ndoi: 10. 1097/JCMA.0000000000001028  \nCopyright © 2023, the Chinese Medical Association. This is an open access article under the CC BY-NC-ND license ([http://creativecommons.org/licenses/](http://creativecommons.org/licenses/)[ ](http://creativecommons.org/licenses/)[by-nc-nd/4.0/](by-nc-nd/4.0/))  \nmetastatic HNSCC patients after progression on ICIs,1 these patients seemed to have a very worsened outcome and finally died of disease.  \nPrecision oncology approach for R/M HNSCC is necessary partly because of its dismal prognosis and therapeutic challenge. As shown by authors,1 the anti-EGFR and ICIs are the present front-line t","cbCailItJQdYIoft","https://ap.wps.com/l/cbCailItJQdYIoft","pdf",264112,"English","# Editorial\n## Context and cancer challenge\n## Cetuximab after progression on ICIs\n## Survival outcomes and interpretation\n## Precision oncology and candidate selection\n## Role of chemoradiotherapy, CRT, and radiosensitizers","[{\"question\":\"What treatment challenge does the editorial address in recurrent or metastatic HNSCC?\",\"answer\":\"It addresses patients with recurrent (or loco-regional) and metastatic head and neck squamous cell carcinoma who progressed after immune checkpoint inhibitors, highlighting the difficulty of improving outcomes.\"},{\"question\":\"How was cetuximab evaluated after progression on ICIs, and what were the key results?\",\"answer\":\"The study enrolled 28 patients and reported objective response rate and disease control rate, with median progression-free survival of 2.9 months and median overall survival of 8.4 months.\"},{\"question\":\"Why does the editorial argue that neither cetuximab nor ICIs work effectively as front-line radiosensitizers?\",\"answer\":\"It notes lack of significant survival improvement when cetuximab is added to CRT and when ICIs are combined with CRT, and therefore positions radiosensitizing systemic therapy as an unmet need requiring new agents and strategy design.\"}]","Winners of the 2022 honor awards for excellence at the annual meeting of the Chinese Medical Association-Taipei - Part IV | PDF",1790665331]